2015 News

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

December 11, 2015

Morphotek's Run to Bring Hope Home
Read More

December 7, 2015

Morphotek Announces Phase 1 Results From MORAb-022-001 Trial in Healthy Subjects and Patients with Mild-to-Moderate Rheumatoid Arthritis
Read More

December 3, 2015

Morphotek Announces Collaboration Agreement with University of Wisconsin-Madison to Study the Immunosuppressive Effects of CA125 Tumor Antigen on Immune-Based Therapies for Ovarian Cancer
Read More

November 18, 2015

Morphotek, Inc. Announces Initiation of Amatuximab Study in First-Line, Unresectable, Malignant Pleural Mesothelioma Patients
Read More

November 17, 2015

Morphotek Announces Collaboration Agreement With University of Gothenburg to Develop Farletuzumab, an Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, for Alpha-Particle Radioimmunotherapy in Ovarian Cancer
Read More

November 9, 2015

Morphotek, Inc. Announces a License Agreement With Blaze Bioscience Inc. For The Development of Novel Oncology Imaging Technology
Read More

October 26, 2015

Morphotek, Inc. Presents Preclinical Findings at ESGO 19 on the Potential Immuno-suppressive Effects of the CA125 Tumor Antigen on Farletuzumab, an Investigational Anti-folate Receptor Alpha Antibody
Read More

April 6, 2015

Morphotek Participates in 2015 GETT Expo
Read More

March 30, 2015

Morphotek, Inc. Announces Initiation of Farletuzumab Study in Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels of the Immunosuppressive CA125 Tumor Antigen
Read More

February 16, 2015

Morphotek, Inc. Recognized as Top 25 Life Sciences Companies in the Greater Philadelphia Area
Read More

News & Events > News Archive > 2015 News